Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

• Biotage^® PeptiPEC high-throughput kits facilitate fast and low solvent consumption solution for plate-based peptide purification
• Partnership complements Gyros’ PurePep^® EasyClean technology offering with an automated solution for advanced discovery process

UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, and Biotage, a global life sciences company, providing high-quality purification and sample preparation solutions, today announced a partnership to offer Biotage^® PeptiPEC, based on Gyros’ PurePep^® EasyClean (PEC^™) catch and release technology, on Biotage^® Extrahera^™ automated sample preparation system. The development of an automated plate-based peptide purification workflow provides a fast and environmentally sustainable solution for high-throughput peptide purification.

Biotage PeptiPEC high-throughput kits leverage Gyros Protein Technologies’ proprietary PEC catch and release technology for automation in a plate-based format, enabling scientists to now use the technology to advance drug discovery processes. The PEC technology combined with Biotage Extrahera can purify up to 96 peptides in parallel 75% faster and 98% lower solvent consumption in comparison to sequential HPLC.

Parallel peptide synthesis generates crude peptide samples at a rate that surpasses the capacity of HPLC, the most common method of peptide purification, which is particularly evident when purifying more than 24 peptides simultaneously. The workflow enables scientists to conduct screening and development processes using purified peptides, supporting more robust and accurate processes and results.

Tomas Blomquist, CEO, Biotage, said: “We’re excited to be partnering with Gyros Protein Technologies to bring a plate-based automated solution for parallel high-throughput peptide purification to market, removing bottlenecks for peptide scientists, and providing a complete workflow solution from synthesis to evaporation. This partnership strengthens our position in the rapidly growing peptide market and supports our mission to provide high-quality, end-to-end separation and sample preparation solutions to scientists all over the world.”

Mark Vossenaar, Vice President, General Manager, Biopharmaceutical Development Division at Mesa Labs, commented: “By partnering with Biotage, we are taking a step further in our commitment to provide scientists with state-of-the-art peptide solutions across the entire value chain, from early research and screening to large-scale peptide production. The availability of our proprietary PEC purification for automation in a plate-based format is equipping researchers with faster and more sustainable processes to advance their drug discovery."